Open Access<p>Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations</p>
Author(s) -
Omar Usmani,
Nicola Scichilone,
B Mignot,
Dennis Belmans,
Cedric Van Holsbeke,
Jan De Backer,
Roberta De Maria,
Erika Cuoghi,
Eva Topole,
George Georges
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s269001
Subject(s) - medicine , copd , bronchodilator , inhalation , fluticasone propionate , inhaler , dry powder inhaler , lung volumes , anesthesia , asthma , lung
There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructive pulmonary disease (COPD), and it is therefore important that inhalation therapy (both bronchodilator and anti-inflammatory) can deposit in the small airways. Two single-inhaler triple therapy (SITT) combinations are currently approved for the maintenance treatment of COPD: extrafine formulation beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB), and non-extrafine formulation fluticasone furoate/vilanterol/umeclidinium (FluF/VI/UMEC). This study evaluated the lung deposition of the inhaled corticosteroid (ICS), long-acting β 2 -agonist (LABA), and long-acting muscarinic antagonist (LAMA) components of these two SITTs.